You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Based on the growth in test volume and revenue, the company increased its volume and revenue guidance for the year.
Rapid immunoassay product revenues — including sales from the firm's QuickVue, Sofia, and Eye Health products — rose 40 percent year over year.
Total sample-to-answer molecular product revenue for the first quarter of 2018 was $16.5 million, representing 49 percent growth.
Although revenues from the firm's global diagnostics business were down 6 percent year over year, molecular diagnostic product revenues were up 6 percent.
In 2018, the company expects to place between 140 and 170 new ePlex analyzers, and an annuity per ePlex in the $100,000 to $120,000 range.
The company said it also saw record cash collections in the quarter despite challenges caused by regulatory change.
The company said revenues in its diagnostics business unit rose 62 percent during the quarter.
The company said test volume rose 87 percent to 186,000 during the quarter.
Lifted by a strong flu season, Cobas Liat PCR placements reached 1,500 systems in the US. Globally, year-over-year sales for the point-of-care system grew 262 percent.
The company said it had a large uptick in testing revenues during the quarter, including for its AlloSure kidney transplant test, which was launched in October.
Springer Nature announces €9,500 fee to make papers open-access in Nature and its family of journals.
Librarians have concluded that notebooks that belonged to Charles Darwin that were thought to have been lost were actually likely stolen, CNN reports.
An early SARS-CoV-2 alteration may have enabled it to spread more easily, according to the New York Times.
In PNAS this week: ultrarare variants contribute to aging-related hearing loss, telomeres of cells infected with herpesvirus, and more.